Kurz gefasst
Fachartikel in der Zeitschrift Janeway, erschienen am 31.03.2024. Verfasst von Faatimah Patel.
Abstract (Originalsprache)
Patented in 1984 and approved for medical use in 1995, Anastrozole has become one of the most prescribed drugs for postmenopausal women to prevent the development of breast cancer. It works by lowering the oestrogen levels of postmenopausal women and slows or reverses the growth of hormone receptor-positive breast cancer. Anastrozole is often given to patients whose cancer has progressed even after taking the drug Tamoxifen, which also works by lowering oestrogen levels. There are many side effects that come with Anastrozole, so precaution must be taken when prescribing the drug because the side effects will vary depending on how it interacts and metabolises within the patient’s body. Research is being conducted to test if the effectiveness of Anastrozole can be increased if taken with other drugs, such as palbociclib; however, the economic costs on health institutions around the world must be considered. It may also be possible for Anastrozole to be genotyped for a specific individual to maximise its effect and reduce the risk of developing the side effects.
Schlagwörter
Zitieren
APA
Patel, F. (2024). Anastrazole: Preventing Breast Cancer. Janeway. https://doi.org/10.57898/biosci.183
Vancouver
Patel F. Anastrazole: Preventing Breast Cancer. Janeway. 2024. doi:10.57898/biosci.183
BibTeX
@article{Patel2024,
author = {Patel, Faatimah},
title = {Anastrazole: Preventing Breast Cancer},
journal = {Janeway},
year = {2024},
doi = {10.57898/biosci.183}
}
EUVIMED